Walleye Capital LLC acquired a new position in shares of Rallybio Co. (NASDAQ:RLYB – Get Rating) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 59,543 shares of the company’s stock, valued at approximately $416,000.
Several other institutional investors and hedge funds have also bought and sold shares of RLYB. California State Teachers Retirement System lifted its position in Rallybio by 124.8% during the first quarter. California State Teachers Retirement System now owns 7,694 shares of the company’s stock worth $54,000 after purchasing an additional 4,272 shares during the period. American International Group Inc. raised its stake in Rallybio by 134.9% during the first quarter. American International Group Inc. now owns 8,984 shares of the company’s stock worth $63,000 after acquiring an additional 5,160 shares in the last quarter. Rhumbline Advisers acquired a new position in Rallybio during the first quarter worth about $91,000. Goldman Sachs Group Inc. raised its stake in Rallybio by 17.0% during the first quarter. Goldman Sachs Group Inc. now owns 15,289 shares of the company’s stock worth $107,000 after acquiring an additional 2,224 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Rallybio by 145.6% during the first quarter. Bank of New York Mellon Corp now owns 41,688 shares of the company’s stock worth $291,000 after acquiring an additional 24,711 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, JMP Securities upped their price objective on Rallybio from $29.00 to $34.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 9th.
Rallybio Price Performance
Rallybio (NASDAQ:RLYB – Get Rating) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.04. Equities analysts anticipate that Rallybio Co. will post -2.16 EPS for the current year.
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- Get a free copy of the StockNews.com research report on Rallybio (RLYB)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.